Identification of seven new prostate cancer susceptibility loci through a genome-wide association study

Prostate cancer (PrCa) is the most frequently diagnosed cancer in males in developed countries. To identify common PrCa susceptibility alleles, we previously conducted a genome-wide association study in which 541,129 SNPs were genotyped in 1,854 PrCa cases with clinically detected disease and in 1,894 controls. We have now extended the study to evaluate promising associations in a second stage in which we genotyped 43,671 SNPs in 3,650 PrCa cases and 3,940 controls and in a third stage involving an additional 16,229 cases and 14,821 controls from 21 studies. In addition to replicating previous associations, we identified seven new prostate cancer susceptibility loci on chromosomes 2, 4, 8, 11 and 22 (with P = 1.6 × 10−8 to P = 2.7 × 10−33).

Ali Amin Al Olama | T. Sellers | D. Schaid | D. English | J. Morrison | T. Rebbeck | R. Eeles | Z. Kote-Jarai | G. Giles | M. Guy | G. Severi | K. Muir | J. Hopper | B. Henderson | C. Haiman | J. Schleutker | F. Hamdy | D. Neal | J. Donovan | J. Stanford | E. Ostrander | S. Ingles | E. John | S. Thibodeau | Jong Y. Park | A. Spurdle | J. Clements | J. Dickinson | C. Maier | W. Vogel | T. Dörk | K. Cooney | L. Cannon-Albright | P. Chappuis | P. Hutter | M. Zeegers | R. Kaneva | Hong-wei Zhang | Yong-jie Lu | W. Foulkes | D. Leongamornlert | M. Tymrakiewicz | A. Ardern-Jones | A. Hall | L. O'Brien | R. Wilkinson | E. Saunders | E. Page | E. Sawyer | S. Edwards | D. Dearnaley | A. Horwich | R. Huddart | V. Khoo | C. Parker | N. V. As | C. Woodhouse | A. Thompson | T. Christmas | C. Ogden | C. Cooper | M. Southey | A. Lophatananon | Jo-Fen Liu | L. Kolonel | L. Marchand | Tiina Wahlfors | T. Tammela | A. Auvinen | S. Lewis | A. Cox | L. FitzGerald | J. Koopmeiners | D. Karyadi | E. Kwon | M. Stern | R. Corral | A. Joshi | Ahva Shahabi | S. McDonnell | J. Pow-Sang | S. Chambers | J. Aitken | R. Gardiner | J. Batra | M. Kedda | F. Lose | A. Polanowski | B. Patterson | J. Serth | A. Meyer | M. Luedeke | Klara Stefflova | A. Ray | E. Lange | Jim Farnham | Humera S. Khan | C. Slavov | A. Mitkova | G. Cao | D. Easton | L. Le Marchand | A. A. Al Olama | N. Van As | J. Hopper | A. Ardern-jones | H. Khan | D. E. Neal | Jong Y. Park | C. Haiman | Christopher C. Parker | Yong-jie Lu | Graham G. Giles | D. Neal | John L. Hopper | Sarah J Lewis | A. Olama | William D. Foulkes | Esther M. John | D. Easton | Ethan M. Lange | B. E. Henderson | Manuel Luedeke | Kathleen A. Cooney | Jenny L. Donovan | David P. Dearnaley | S. Thibodeau | Joanne L Dickinson | R. Huddart | Vincent S Khoo | Christopher C Parker | Nicholas J Van As | Colin S Cooper | Amit D. Joshi | R. A. Gardiner | Román Corral | D. Dearnaley | Colin S. Cooper | J. Donovan | N. V. As

[1]  D. English,et al.  Smoking and prostate cancer: findings from an Australian case-control study. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  D. English,et al.  Androgenetic alopecia and prostate cancer: findings from an Australian case-control study. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[3]  C. Bieberich,et al.  NKX-3.1 interacts with prostate-derived Ets factor and regulates the activity of the PSA promoter. , 2002, Cancer research.

[4]  J. Bullerdiek,et al.  Identification of a gene rearranged by 2p21 aberrations in thyroid adenomas , 2003, Oncogene.

[5]  D. English,et al.  ELAC2/HPC2 polymorphisms, prostate-specific antigen levels, and prostate cancer. , 2003, Journal of the National Cancer Institute.

[6]  D Gillatt,et al.  Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. , 2003, Health technology assessment.

[7]  C. Ji,et al.  Cloning and Identification of a Novel Human Gene PDLIM5, a Homolog of AD-associated Neuronal Thread Protein (AD7c-NTP) , 2004, DNA sequence : the journal of DNA sequencing and mapping.

[8]  M. Gleave,et al.  NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. , 2006, Cancer cell.

[9]  N. Camp,et al.  Localization of a prostate cancer predisposition gene to an 880-kb region on chromosome 22q12.3 in Utah high-risk pedigrees. , 2006, Cancer research.

[10]  Y. Bang,et al.  Histone Deacetylase Inhibitors for Cancer Therapy , 2006, Epigenetics.

[11]  A. Whittemore,et al.  Multiple regions within 8q24 independently affect risk for prostate cancer , 2007, Nature Genetics.

[12]  P. Fearnhead,et al.  Genome-wide association study of prostate cancer identifies a second risk locus at 8q24 , 2007, Nature Genetics.

[13]  D. Gudbjartsson,et al.  Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes , 2007, Nature Genetics.

[14]  Adam S. Kibel,et al.  A common variant associated with prostate cancer in European and African populations , 2007 .

[15]  A. Whittemore,et al.  Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics. , 2007, Human molecular genetics.

[16]  Lester L. Peters,et al.  Genome-wide association study identifies novel breast cancer susceptibility loci , 2007, Nature.

[17]  J. Bullerdiek,et al.  A domain of the thyroid adenoma associated gene (THADA) conserved in vertebrates becomes destroyed by chromosomal rearrangements observed in thyroid adenomas. , 2007, Gene.

[18]  D. Schaid,et al.  Fine mapping of familial prostate cancer families narrows the interval for a susceptibility locus on chromosome 22q12.3 to 1.36 Mb , 2008, Human Genetics.

[19]  D. Gudbjartsson,et al.  Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24 , 2007, Nature Genetics.

[20]  D. Clayton,et al.  An R Package for Analysis of Whole-Genome Association Studies , 2007, Human Heredity.

[21]  Elaine A. Ostrander,et al.  Multiple Novel Prostate Cancer Predisposition Loci Confirmed by an International Study: The PRACTICAL Consortium , 2008, Cancer Epidemiology Biomarkers & Prevention.

[22]  M. McCarthy,et al.  Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes , 2008, Nature Genetics.

[23]  G. Giaccone,et al.  Histone deacetylase inhibitors in cancer therapy , 2008, Current opinion in oncology.

[24]  R. Eeles,et al.  SNPs in the kallikrein gene region associated with prostate cancer risk: true cause or association by design? , 2008, Nature genetics.

[25]  M. Thun,et al.  Variation in KLK genes, prostate-specific antigen and risk of prostate cancer , 2008, Nature Genetics.

[26]  R. Nagle,et al.  The Role of Alpha 6 Integrin in Prostate Cancer Migration and Bone Pain in a Novel Xenograft Model , 2008, PloS one.

[27]  R. Weindruch,et al.  Aging and cancer-related loss of insulin-like growth factor 2 imprinting in the mouse and human prostate. , 2008, Cancer research.

[28]  J. Brooks.  Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer , 2008 .

[29]  R. Eeles,et al.  Reply to “Variation in KLK genes, prostate-specific antigen and risk of prostate cancer” , 2008, Nature Genetics.

[30]  W. Willett,et al.  Multiple loci identified in a genome-wide association study of prostate cancer , 2008, Nature Genetics.

[31]  E. Gelmann,et al.  R E V Ie W a Rt I C L E , 2022 .

[32]  Jungwon Huh,et al.  Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. , 2009, Blood.

[33]  John S. Witte,et al.  Prostate cancer genomics: towards a new understanding , 2009, Nature Reviews Genetics.

[34]  A. Kibel.  Multiple newly identified loci associated with prostate cancer susceptibility , 2009 .